Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The Mectizan Donation Programme--a 10-year report

H B Dull1, S E Meredith

  • 1Task Force for Child Survival and Development, Atlanta, GA 30307, USA. bdull@taskforce.org

Annals of Tropical Medicine and Parasitology
|December 23, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Onchocerciasis: The First Decade of Mectizantrade mark Treatment.

Parasitology today (Personal ed.)·2006
Same author

The effect of 5 years of annual treatment with ivermectin (Mectizan) on the prevalence and morbidity of onchocerciasis in the village of Gami in the Central African Republic.

Annals of tropical medicine and parasitology·2002
Same author

DNA in situ hybridization on polytene chromosomes of Simulium sanctipauli at loci relevant to insecticide resistance.

Medical and veterinary entomology·2000
Same author

Biochemical and molecular characterization of Leishmania parasites isolated from an endemic focus in eastern Sudan.

Transactions of the Royal Society of Tropical Medicine and Hygiene·1998
Same author

The direct agglutination test for diagnosis of visceral leishmaniasis under field conditions in Sudan: comparison of aqueous and freeze-dried antigens.

Transactions of the Royal Society of Tropical Medicine and Hygiene·1998
Same author

Sensitivity of a polymerase chain reaction-based assay to detect Onchocerca volvulus DNA in skin biopsies.

Parasitology research·1996
Same journal

Some observations upon the maintenance of Australorbis glabratus in the laboratory.

Annals of tropical medicine and parasitology·2014
Same journal

A new species of Phlebotomus (Diptera, Psychodidae) from Uganda.

Annals of tropical medicine and parasitology·2014
Same journal

The length of exposure to infestation and the danger of contracting onchocerciasis.

Annals of tropical medicine and parasitology·2014
Same journal

Observations on Chrysops silacea and C. dimidiata at Benin, Southern Nigeria. II.

Annals of tropical medicine and parasitology·2014
Same journal

Embryonated eggs of Ascaris lumbricoides in the wall of a human hernial sac.

Annals of tropical medicine and parasitology·2014
Same journal

Studies in the chemotherapy of cholera. VI. Protection by pteridines of mice infected with Vibrio cholerae.

Annals of tropical medicine and parasitology·2014
See all related articles

Merck & Co. has donated over 96 million Mectizan (ivermectin) treatments for onchocerciasis since 1987. This donation program has provided essential treatment to millions globally, with ongoing support expected.

Area of Science:

  • Global Health
  • Infectious Diseases
  • Pharmacology

Background:

  • Onchocerciasis, a parasitic disease, poses a significant health burden in endemic regions.
  • Mectizan (ivermectin) is a safe and effective microfilaricide for treating onchocerciasis.
  • A long-term donation program was established to ensure widespread access to Mectizan.

Purpose of the Study:

  • To evaluate the impact and reach of Merck & Co.'s Mectizan donation program for onchocerciasis treatment.
  • To highlight the scale of Mectizan distribution and patient access over a decade.

Main Methods:

  • The study analyzes data from Merck & Co.'s Mectizan donation program.
  • It tracks the number of treatments enabled and distributed in endemic countries.
  • Patient access and cumulative dosing are estimated based on program records.

Related Experiment Videos

Main Results:

  • Over 96 million Mectizan treatments have been facilitated since the program's inception in 1987.
  • The program supports community-based treatment in 34 endemic countries across Africa, the Middle East, and Latin America.
  • An estimated 19-20 million individuals have received at least one dose, with many receiving multiple annual treatments.

Conclusions:

  • The Mectizan donation program has significantly expanded access to onchocerciasis treatment globally.
  • Sustained donation efforts are crucial for continued disease management and public health improvement.
  • The program demonstrates a successful model for pharmaceutical companies contributing to global health initiatives.